🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Investors Underestimate Power Of This Pieced Flywheel: Analyst Kicks Off Coverage On CVS Health

Published 21/04/2023, 20:52
© Reuters.  Investors Underestimate Power Of This Pieced Flywheel: Analyst Kicks Off Coverage On CVS Health
CVS
-
CVSH34
-

Benzinga -

  • As a part of a broader coverage of 15 companies in the Healthcare Services sector, Cantor Fitzgerald initiated coverage on CVS Health Corp (NYSE: CVS) with a price target of $87 and an Overweight rating.
  • Once pieced together, CVS, Signify Health, Oak Street Health Inc (NYSE: OSH), and Carbon (JV) can create a flywheel that brings in industry-leading, consumer-facing technology and ease of access, enhanced brand value across commercial and Medicare, higher NPS (net promoter score), and significantly more opportunities.
  • Also Read: New York Governor, Attorney General Ask Three Pharmacy Operators' Commitment Over Abortion Drug Access.
  • The analyst sees potential for a bull scenario of long-term revenue synergies.
  • Cantor says adj EPS guided of $9.00 in 2024 and $10.00 in 2025, a 6.6% CAGR off 2022 adjusted baseline of $8.25, assumes low- to mid-single-digit health care benefits and mid-single-digit pharmacy growth, OSH closes in 2023, and SGFY closes in 2Q23 with positive earnings contribution in 2024.
  • The analyst estimates bull scenario could generate $10.50-$11.00.
  • Under the leadership of Vijay Patel, the analyst writes that the portfolio could grow to an alpha-generating and self-financing $1 billion portfolio. It says the selections represent an astute recognition of competitive and sustainable advantages.
  • Price Action: CVS shares are down 0.52% at $72.87 on the last check Friday.
Latest Ratings for CVS DateFirmActionFromTo
Feb 2022Raymond JamesDowngradesStrong BuyOutperform
Dec 2021Tigress FinancialMaintainsBuy
Dec 2021MizuhoMaintainsBuy
View More Analyst Ratings for CVS

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.